On 19 September 2001, orphan designation (EU/3/01/059) was granted by the European Commission to TopoTarget A/S, Denmark, for dexrazoxane for the treatment of anthracycline extravasation.
The sponsorship was transferred to SpePharm Holding B.V., The Netherlands, in September 2010 and subsequently to Norgine B.V.,The Netherlands, in September 2013. In July 2014 the sponsorship was transferred to Clinigen Healthcare Ltd., United Kingdom.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
|Disease / condition||
Treatment of anthracycline extravasations
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;